Evidence map›Paper›PMID 42172090›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.

Jiale Zhang, Hui Shi, Chen Wang, Zihao Liu, Lianxin Zhou, Xinyu Lv, Mengjie Guo, Ye Yang, Chunyan Gu

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiale ZhangNanjing Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Hui ShiSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Chen WangSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Zihao LiuSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Lianxin ZhouSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Xinyu LvSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Mengjie GuoSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Ye YangSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0003-0228-5102
Chunyan GuNanjing Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0001-7408-8840

Funding

Climbing Plan of Basic Research Priorities Program of Jiangsu Province BK20240003National Natural Science Foundation of China 82373936
6 · The paper itself

Abstract

Developing anticancer strategies that simultaneously target both tumor proliferation and the immunosuppressive microenvironment remains a major challenge. However, the role of chemical modifications in circular RNAs (circRNAs) in this process remains poorly understood. In this study, we identified circANKRD12 as a key substrate for N

Indexed as

AcetyltransferasesMultiple MyelomaRNA, CircularTumor MicroenvironmentAnimalsCell Line, TumorCell ProliferationHistone Deacetylase 2HumansMiceAcetyltransferasesHistone Deacetylase 2RNA, CircularcircANKRD12desloratadinemultiple myelomaN4‐acetylcytidineN‐acetyltransferase 10

Identifiers

PMID42172090
PMCPMC13336040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.